Elsevier

Veterinary Parasitology

Volume 87, Issue 4, 1 February 2000, Pages 327-338
Veterinary Parasitology

Rapid communication
Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle

https://doi.org/10.1016/S0304-4017(99)00175-2Get rights and content

Abstract

Pharmacokinetic studies have been used traditionally to characterize drug concentration profiles achieved in the bloodstream. However, endectocide molecules exert their persistent and broad spectrum activity against parasites localized in many different tissues. The aim of this study was to compare the distribution of ivermectin (IVM) and doramectin (DRM) to different tissues in which parasites are found following subcutaneous administration to calves. Holstein calves weighing 120–140 kg were injected in the shoulder area with commercially available formulations of IVM (Ivomec 1% MSD AGVET, NJ, USA) (Group A) or DRM (Dectomax 1%, Pfizer, NY, USA) (Group B). Two treated calves were sacrificed at 1, 4, 8, 18, 28, 38, 48 or 58 days post-treatment. Plasma, abomasal and small intestinal fluids and mucosal tissues, bile, faeces, lung and skin samples were collected, extracted, derivatized and analyzed by high performance liquid chromatography (HPLC) with fluorescence detection to determine IVM and DRM concentrations. IVM and DRM were distributed to all the tissues and fluids analyzed. Concentrations >0.1 ng/ml (ng/g) were detected between 1 and 48 days post-treatment in all the tissues and fluids investigated. At 58 days post-treatment, IVM and DRM were detected only in bile and faeces, where large concentrations were excreted. Delayed Tmax values for DRM (4 days post-administration) compared to those for IVM (1 day) were observed in the different tissues and fluids. High IVM and DRM concentrations were measured in the most important target tissues, including skin. The highest IVM and DRM concentrations were measured in abomasal mucosa and lung tissue. Enhanced availabilities of both IVM (between 45 and 244%) and DRM (20–147%) were obtained in tissues compared to plasma. There was good correlation between concentration profiles of both compounds in plasma and target tissues (mucosal tissue, skin, and lung). Drug concentrations in target tissues remained above 1 ng/g for either 18 (IVM) or 38 (DRM) days post-treatment. The characterization of tissue distribution patterns contributes to our understanding of the basis for the broad-spectrum endectocide activity of avermectin-type compounds.

Introduction

The avermectins are naturally occurring compounds produced by fermentation of the soil-dwelling actinomycete Streptomyces avermitilis. Ivermectin (IVM), a semi-synthetic derivative of avermectin B1, consists of an 80 : 20 mixture of the equipotent homologous 22,23 dehydro B1a and B1b (Fisher and Mrozik, 1989). Doramectin (DRM) is an avermectin compound obtained by mutational biosynthesis, produced by feeding cyclohexane carboxylic acid to a genetically engineered strain of S. avermitilis and, as a result, has a cyclohexyl group at the C25 position (Goudie et al., 1993). IVM and DRM are endectocide compounds with exceptional potency and broad nematode and arthropod spectrum of activity (McKellar and Benchaoui, 1996). The plasma disposition kinetics of ivermectin have been studied in different species. The comparative plasma kinetic profiles of IVM and DRM following subcutaneous administration to cattle has been characterized recently (Lanusse et al., 1997, Toutain et al., 1997). Drugs are distributed throughout the body in the circulating blood and must diffuse to target tissues to exert systemic effects. Concentrations attained in the tissues depend on the ability of the drug to penetrate capillary endothelium and diffuse across cell membranes (Baggot, 1977), where lipophilicity plays a role. Therefore, the distribution process to different tissues varies widely for different drug molecules (Eichler and Müller, 1998).

Pharmacokinetic trials have traditionally focused on drug concentration profiles achieved in the bloodstream. However, many drugs exert their effects in defined non-vascular target tissues into which they must be distributed from the central blood compartment. Endectocide molecules exert their persistent and broad spectrum activity against parasites located in widely different tissues, such as different skin layers (sites of location of arthropod parasites and warble flies), the gastrointestinal (GI) and pulmonary tracts, in which nematode parasites develop. Ivermectin concentration profiles in GI mucus and fluids of cattle and sheep have been reported previously (Bogan and McKellar, 1988). There is no available information on the tissue distribution pattern of DRM in cattle. The characterization of IVM and DRM concentrations attained at specific sites of parasite location and the relationship between their plasma concentration profiles and those attained at the sites of location of internal and external target parasites, is unknown. The aim of this study was to characterize the comparative distribution pattern of IVM and DRM to different target tissues following their subcutaneous administration to calves.

Section snippets

Experimental animals

Thirty-three 10-month old, castrated male Holstein calves weighing 120–140 kg were used in this trial. Animals were raised in parasite-free conditions checked by faecal egg per gram (EPG) counts and grazed on a lucerne/red and white clover pasture prior to and during the experimental period. Water was provided ad libitum. The health of the calves was closely monitored prior to and throughout the trial.

Treatments and tissue sample collections

Animal were randomly divided into two groups and treated with either IVM (Ivomec 1% MSD AGVET,

Results

High concentrations of IVM and DRM were measured at the most important target tissues; concentrations >0.10 ng/g (or ng/ml) were detected for as long as 48 days post-treatment. The highest drug concentrations were obtained in abomasal mucosa for IVM (AUC: 959 ng day/g) and in lung tissue for DRM (AUC: 1351 ng day/g). Drug concentrations in abomasal and intestinal mucosal tissue between 18 and 48 days post-treatment, ranged from 20.9 to 0.13 ng/g for DRM and from 3.76 to 0.10 ng/g for IVM. The

Discussion

In agreement with previously published data (Lanusse et al., 1997, Toutain et al., 1997), the use of an oil-based formulation of DRM in the current trial resulted in delayed absorption from the site of subcutaneous administration compared to the non-aqueous formulation of IVM. The slow release of DRM from the subcutaneous depot of the oily vehicle is consistent with the observation that peak concentrations in different tissues and fluids were attained at 4 days post-treatment, while those of

Acknowledgements

Adrián L. Lifschitz is a recipient of a Doctoral Fellowship from the Consejo Nacional de Investigaciones Cientı́ficas y Técnicas (CONICET) (Argentina). This study was partially supported by CONICET (Argentina), Universidad Nacional del Centro (Argentina) and Agencia Nacional de Promoción Cientı́fica y Tecnológica (PICT 08-00000-00817) Argentina.

References (24)

  • Baggot, J., 1977. Principles of Drug Disposition: The Basis of Veterinary Clinical Pharmacology. W.B Saunders,...
  • Benz, G.W., Roncalli, R.A., Gross, S.J., 1989. Use of ivermectin in cattle, sheep, goats and swine. In: Campbell, W.C....
  • Cited by (165)

    View all citing articles on Scopus
    View full text